Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity

被引:108
作者
Brunstein, Claudio G. [1 ]
Wagner, John E. [1 ]
Weisdorf, Daniel J. [1 ]
Cooley, Sarah [1 ]
Noreen, Harriet [1 ]
Barker, Juliet N. [1 ]
DeFor, Todd [1 ]
Verneris, Michael R. [1 ]
Blazar, Bruce R. [1 ]
Miller, Jeffrey S. [1 ]
机构
[1] Univ Minnesota, Ctr Canc, Blood & Marrow Transplant Program, Div Hematol Oncol & Transplantat,MMC 806, Minneapolis, MN 55455 USA
基金
美国国家卫生研究院;
关键词
NATURAL-KILLER-CELLS; VERSUS-HOST-DISEASE; BONE-MARROW; LIGAND INCOMPATIBILITY; UNRELATED DONORS; NK CELLS; T-CELLS; OUTCOMES; GRAFT; ADULTS;
D O I
10.1182/blood-2008-12-197467
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We examined the clinical impact of killer-immunoglobulin receptor-ligand (KIR-L) mismatch in 257 recipients of single (n = 91) or double (n = 166) unit umbilical cord blood (UCB) grafts after myeloablative (n = 155) or reduced intensity (n = 102) conditioning regimens. Analyses of double unit grafts considered the KIR-L match status of the dominant engrafting unit. After myeloablative conditioning, KIR-L mismatch had no effect on grade III-IV acute graft-versus-host disease (GVHD), transplantation-related mortality (TRM), relapse, and survival. In contrast, after reduced intensity conditioning, KIR-L mismatch between the engrafted unit and the recipient resulted in significantly higher rates of grade III-IV acute GVHD (42% [CI, 27-59] vs 13% [CI, 5-21], P < .01) and TRM (27% [CI, 12%-42%] vs 12% [CI, 5%-19%], P = .03) with inferior survival (32% [CI, 15%-59%] vs 52% [CI, 47%-67%], P = .03). Multivariate analysis identified KIR-L mismatch as the only predictive factor associated with the development of grade III-IV acute GVHD (RR, 1.8 [CI, 1.1-2.9]; P = .02) and demonstrated a significant association between KIR-L mismatch and increased risk of death (RR, 1.8; 95% CI, 1.0-3.1; P = .05). Our results do not support the selection of UCB units based on KIR-L status and suggest that KIR-L mismatching should be avoided in reduced intensity UCB transplantation. (Blood. 2009; 113: 5628-5634)
引用
收藏
页码:5628 / 5634
页数:7
相关论文
共 38 条
  • [1] Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy
    Barker, JN
    Weisdorf, DJ
    DeFor, TE
    Blazar, BR
    McGlave, PB
    Miller, JS
    Verfaillie, CM
    Wagner, JE
    [J]. BLOOD, 2005, 105 (03) : 1343 - 1347
  • [2] Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning
    Barker, JN
    Weisdorf, DJ
    DeFor, TE
    Blazar, BR
    Miller, JS
    Wagner, JE
    [J]. BLOOD, 2003, 102 (05) : 1915 - 1919
  • [3] NK cells recover early and mediate cytotoxicity via perforin/granzyme and Fas/FasL pathways in umbilical cord blood recipients
    Brahmi, Z
    Hommel-Berrey, G
    Smith, F
    Thomson, B
    [J]. HUMAN IMMUNOLOGY, 2001, 62 (08) : 782 - 790
  • [4] Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease
    Brunstein, Claudio G.
    Barker, Juliet N.
    Weisdorf, Daniel J.
    DeFor, Todd E.
    Miller, Jeffrey S.
    Blazar, Bruce R.
    McGlave, Philip B.
    Wagner, John E.
    [J]. BLOOD, 2007, 110 (08) : 3064 - 3070
  • [5] Human natural killer cells
    Caligiuri, Michael A.
    [J]. BLOOD, 2008, 112 (03) : 461 - 469
  • [6] KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation
    Cooley, S
    McCullar, V
    Wangen, R
    Bergemann, TL
    Spellman, S
    Weisdorf, DJ
    Miller, JS
    [J]. BLOOD, 2005, 106 (13) : 4370 - 4376
  • [7] COX DR, 1972, J R STAT SOC B, V187, P220
  • [8] Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants
    Davies, SM
    Ruggieri, L
    DeFor, T
    Wagner, JE
    Weisdorf, DJ
    Miller, JS
    Velardi, A
    Blazar, BR
    [J]. BLOOD, 2002, 100 (10) : 3825 - 3827
  • [9] Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    Dudley, ME
    Wunderlich, JR
    Yang, JC
    Sherry, RM
    Topalian, SL
    Restifo, NP
    Royal, RE
    Kammula, U
    White, DE
    Mavroukakis, SA
    Rogers, LJ
    Gracia, GJ
    Jones, SA
    Mangiameli, DP
    Pelletier, MM
    Gea-Banacloche, J
    Robinson, MR
    Berman, DM
    Filie, AC
    Abati, A
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2346 - 2357
  • [10] Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514